Theralase® Technologies Inc.

Advancing cancer treatment through light-activated technology. Theralase® Technologies is developing energy-activated molecules designed to target cancer cells, bacteria, and viruses while minimizing damage to healthy tissue. Watch: youtube.com/watch?v=OajgmEoq… 🇨🇦 $TLT.V 🇺🇸 #TLTFF

On Remembrance Day, Theralase® Technologies honours those who served and sacrificed for Canada. We remember their courage and express our gratitude to veterans, service members, and their families. Lest we forget. 🇨🇦 $TLT.V 🇺🇸 #TLTFF

Once completed, the toxicology program for our Rutherrin® energy-activated cancer treatment could lead to a broader clinical development program & create opportunities for future pharmaceutical partnerships & licensing arrangements. Read: newsfilecorp.com/release/314… $TLT.V #TLTFF

Next week, Nov. 16 at 5 PM EST, join us for an exclusive webinar that covers the latest clinical progress of our flagship asset, Ruvidar®. Hear from CEO Roger DuMoulin-White & Lead Principal Investigator Dr. Girish Kulkarni. Register: ordnl.link/Eo919gE 🇨🇦 $TLT.V 🇺🇸 #TLTFF

Join Theralase® Technologies CEO Roger DuMoulin-White and Dr. Neal Shore for a webinar exploring the latest interim Study II clinical results for Ruvidar®, an investigational bladder cancer treatment. Register: ordnl.link/DbGZGg4 🇨🇦 $TLT.V 🇺🇸 #TLTFF

In a recent Stocks To Watch interview, CEO Roger White pointed out that 40% of bladder cancer patients who responded to Ruvidar® treatments during an ongoing clinical study are still cancer-free 15 months later. Watch: ordnl.link/uhQWeU5 🇨🇦 $TLT.V 🇺🇸 #TLTFF

Want to learn more about the interim data from the Ruvidar® Study II? Join our webinar on Nov. 16 at 5 PM EST to hear insights directly from CEO Roger White, along with Lead Principal Investigator Dr. Girish Kulkarni. Register: ordnl.link/LboY5cX 🇨🇦 $TLT.V 🇺🇸 #TLTFF

Subject to satisfactory toxicology results and regulatory approval to begin clinical studies, we plan to commence an adaptive clinical development program of intravenous Rutherrin® for various life-threatening cancers. More: newsfilecorp.com/release/314… 🇨🇦 $TLT.V 🇺🇸 #TLTFF

In a recent interview on Stocks to Watch, CEO Roger White discussed our clinical-stage cancer treatment technology, clinical study results for Ruvidar®, and the potential advantages of our proprietary energy activation system. Watch: ordnl.link/76qKssF 🇨🇦 $TLT.V 🇺🇸 #TLTFF

Some cancer cells evade treatment by entering a dormant state triggered by stress hormones. ETH Zurich scientists have developed a light-controlled molecular switch that destroys the receptors responsible for this survival mode. 🔎 ordnl.link/dSElTB1 🇨🇦 $TLT.V 🇺🇸 #TLTFF

Theralase reports Phase II bladder cancer study results for Ruvidar®: 64.5% complete response, 73.1% total response, and 14.9-month median response duration. Regulatory submissions are being prepared. Read: newsfilecorp.com/release/320… 🇨🇦 $TLT.V 🇺🇸 #TLTFF

Scientists from South Korea & the U.S. now work together to develop a light-activated treatment platform for pancreatic cancer. As a company that's also working on light-activated cancer therapy, we welcome this development. Read: ordnl.link/THLrUQI 🇨🇦 $TLT.V 🇺🇸 #TLTFF

We intend to finish toxicology studies for Rutherrin® in Q4 2026. Through this program, we aim to measure the maximum tolerated dose & corresponding human equivalent dose of Rutherrin® across several cancer types. More: newsfilecorp.com/release/311… 🇨🇦 $TLT.V 🇺🇸 #TLTFF

CEO Roger White appeared on Stocks to Watch to compare our 4-hour Ruvidar® treatment procedure with bladder removal surgery, a 7-hour procedure that he noted carries risks even when performed by skilled surgeons. Watch: ordnl.link/4CAxwD9 🇨🇦 $TLT.V 🇺🇸 #TLTFF

We are currently conducting a toxicology analysis of our cancer treatment Rutherrin®. This analysis will determine the optimum dose for first-in-human clinical studies of Rutherrin® for several types of cancer. Learn more: newsfilecorp.com/release/314… 🇨🇦 $TLT.V 🇺🇸 #TLTFF

Theralase® Technologies will present at the 2026 ThinkEquity Conference in New York. Our CEO, Roger DuMoulin-White, will discuss our EASM technology, clinical development programs, and upcoming corporate objectives. Read: newsfilecorp.com/release/318… 🇨🇦 $TLT.V 🇺🇸 #TLTFF

On @stocks2watch_, CEO Roger White shared the case of a study patient who retained their bladder seven years after a single treatment with Ruvidar®, which is currently being studied for treating a form of bladder cancer. Watch: ordnl.link/vdVw0Go 🇨🇦 $TLT.V 🇺🇸 #TLTFF

While other cancer therapies need complex preparation or cold storage, Ruvidar® is shelf-stable for up to a decade. This stability profile could support broader clinical adoption & partnership interest. Watch our Q2 2026 investor call: ordnl.link/NM9lAnc $TLT.V #TLTFF

Our CEO Roger White recently made an appearance on @stocks2watch_ to discuss the latest progress in our drug development for non-muscle-invasive bladder cancer, plus potential future cancer targets. Watch: youtube.com/watch?v=yeFJUx2w… 🇨🇦 $TLT.V 🇺🇸 #TLTFF